Completed Bones, Joints & Muscles Psychology & Behaviour

A pragmatic randomised controlled trial of screening for osteoporosis in older women

In plain English

AI plain-English summary

Every year, around one in five women over 50 breaks a bone because their skeleton has quietly thinned to the point of failure. Osteoporosis affects roughly 20% of women over 50, but doctors currently have no systematic way to identify who will actually fracture. Existing treatments can cut fracture risk by 35% to 50%, yet without a reliable screening programme, many high-risk women go untreated while others receive drugs they do not need. This trial will test a practical solution: screen every woman aged 70 to 85 for fracture risk, then offer treatment to those flagged as high-risk. Over five years, researchers will compare fracture rates between the screened group and a group receiving usual care. If screening reduces fractures by the hoped-for 20%, the impact would be immediate and concrete. Fewer hip fractures would mean fewer emergency surgeries, fewer hospital stays, and fewer older women losing their ability to live independently. For the NHS, that translates into avoided costs for orthopaedic care, rehabilitation, and social support. For individual women, it means a better chance of staying mobile and in their own homes. The study is a pragmatic trial—it tests whether a simple, scalable screening programme works in real GP practices, not just in a research clinic.

View original technical description
Osteoporosis is a common disease affecting around 20% of women aged over 50 years. The condition causes a ?thinning? of the bones making a sufferer prone to fractures. These fractures, particularly hip fractures, can lead to disability, a loss of independent living and even death. Current treatment for osteoporosis can reduce the risk of fracture by around 35% to 50%. However, predicting which women are at high risk of fracture and therefore would most likely benefit from treatment has so far not been conducted in a comprehensive and systematic manner. This study sets out to trial a method of screening all women aged between 70 and 85 for risk of fracture. Women in that age group recruited to the study will either be screened or managed as usual. Those screened and considered at high risk will be offered treatment by their GPs. All women will be followed for 5 years and, at the end of that period, a comparison of the fractures in the screened group will be made with those in the non-screened group. It is hoped that screening will reduce the number of fractures by around 20%.

View the original record at the funder ↗

Researchers

Alison Heawood (Co-Investigator)Amanda Howe (Co-Investigator)Cyrus Cooper (Co-Investigator)David Torgerson (Co-Investigator)Eugene McCloskey (Co-Investigator)Ian Harvey (Co-Investigator)John Kanis (Co-Investigator)Lee Shepstone (Principal Investigator)Neil Gittoes (Co-Investigator)Richard Fordham (Co-Investigator)Richard Holland (Co-Investigator)Tarnya Marshall (Co-Investigator)Terence O'Neill (Co-Investigator)Timothy Peters (Co-Investigator)

Related Research

Grants with similar aims, by meaning.

Exploring a treatment gap for osteoporosis and fragility fractures in older people with Severe Mental Illness: a retrospective study using UK primary care data
What makes older women want to use preventive medications for osteoporosis? A qualitative study of adherence to osteoporosis medication in the 70–85 agegroup.
Screening for osteoporosis: protocol for an evidence map and umbrella review
MICA: Phase II study of the impact of AZD4017 a selective 11beta-HSD1 inhibitor on biochemical markers of bone turnover in post-menopausal osteopaenia
A map of the evidence for the effectiveness and cost-effectiveness of targeted and population screening for osteoporosis in women

Original classification

Research Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.